Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$48.36 USD

48.36
2,008,935

+0.87 (1.83%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $48.37 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23

by Zacks Equity Research

QIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit from Neuron23's drug candidate for Parkinson's disease.

Zacks Equity Research

QIAGEN's (QGEN) New Syndromic Test to Combat Monkeypox Spread

by Zacks Equity Research

QIAGEN (QGEN) joins the global fight against monkeypox with the launch of its novel QIAstat-Dx Viral Vesicular Panel RUO.

Zacks Equity Research

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.

Zacks Equity Research

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome

by Zacks Equity Research

QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.

Zacks Equity Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?

by Zacks Equity Research

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Qiagen (QGEN) Up 0.1% Since Last Earnings Report?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.

Zacks Equity Research

QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio

by Zacks Equity Research

The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.

Zacks Equity Research

QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer

by Zacks Equity Research

The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.

Zacks Equity Research

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

Zacks Equity Research

Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View

by Zacks Equity Research

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

Zacks Equity Research

Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.

Zacks Equity Research

Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

Zacks Equity Research

QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up

by Zacks Equity Research

QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.

Zacks Equity Research

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.

Zacks Equity Research

DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged

by Zacks Equity Research

Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.

Zacks Equity Research

Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up

by Zacks Equity Research

Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.

Zacks Equity Research

LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.

Zacks Equity Research

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

The robust year-over-year revenue growth across Thermo Fisher's (TMO) Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.

Zacks Equity Research

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.